A sample report on
UK ePharmacy
Market Analysis
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F) www.insights10.com
This report presents a strategic analysis of the UK ePharmacy Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc.
This is one of the most comprehensive reports about the UK ePharmacy Market, and offers unmatched value, accuracy, and expert insights
Report Scope
Report Attribute
Details
Number of Pages
70-80
Base Year for Estimation
2022
Forecast Period
2023-2030
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Report Coverage
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario
Quantitative Units
Revenue in USD Million/Billion (Mn/Bn)
Research Approach
Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology
A Sample Report on UK ePharmacy Market Analysis I Confidential 3
Table of Content
CONTENT
PG. NO.
1. ePharmacy Overview
12-24
1.1. Overview
1.2. UK Overview
1.3. Economic Overview: UK
1.4. ePharmacy Market in UK
1.5. Healthcare Services Market in UK
1.6. Healthcare Scenario in UK
1.7. Health Insurance Coverage: UK
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting
25-29
2.1 Market size and forecasts (Excel and Methodology)
A Sample Report on UK ePharmacy Market Analysis I Confidential 4
Table of Content
CONTENT
PG. NO.
2.2. Market Segmentation
2.2.1. By Product Type
2.2.2. By Type
3. Market Dynamics
30-34
3.1. Market Growth Drivers
3.1.1. Increasing User Penetration of ePharmacy
3.1.2. Accessibility and Convenience
3.1.3. Increasing e-commerce Platform
3.2. Market Restraints
3.2.1. Data Breaches and Cyberthreats
3.2.2. Lack of Specific Legislative Framework
3.2.2. Prescription Verification
A Sample Report on UK ePharmacy Market Analysis I Confidential 5
Table of Content
CONTENT
PG. NO.
4. Competitive Landscape
35-45
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Pharmacy2u
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)
4.2.2. LloydsPharmacy
4.2.2.1. Overview
4.2.2.2. Product Applications & Services
A Sample Report on UK ePharmacy Market Analysis I Confidential 6
Table of Content
CONTENT
PG. NO.
4.2.2.3. Recent Developments
4.2.2.4. Partnerships Ecosystem
4.2.2.5. Financials (Based on Availability)
4.2.3. Chemist4U
4.2.3.1. Overview
4.2.3.2. Product Applications & Services
4.2.3.3. Recent Developments
4.2.3.4. Partnerships Ecosystem
4.2.3.5. Financials (Based on Availability)
4.2.4. The Independent Pharmacy
4.2.4.1. Overview
4.2.4.2. Product Applications & Services
A Sample Report on UK ePharmacy Market Analysis I Confidential 7
Table of Content
CONTENT
PG. NO.
4.2.4.3. Recent Developments
4.2.4.4. Partnerships Ecosystem
4.2.4.5. Financials (Based on Availability)
4.2.5. AYP Healthcare
4.2.5.1. Overview
4.2.5.2. Product Applications & Services
4.2.5.3. Recent Developments
4.2.5.4. Partnerships Ecosystem
4.2.5.5. Financials (Based on Availability)
4.2.6. Well Pharmacy
4.2.6.1. Overview
4.2.6.2. Product Applications & Services
A Sample Report on UK ePharmacy Market Analysis I Confidential 8
Table of Content
CONTENT
PG. NO.
4.2.6.3. Recent Developments
4.2.6.4. Partnerships Ecosystem
4.2.6.5. Financials (Based on Availability)
4.2.7. Superdrug Online Doctor
4.2.7.1. Overview
4.2.7.2. Product Applications & Services
4.2.7.3. Recent Developments
4.2.7.4. Partnerships Ecosystem
4.2.7.5. Financials (Based on Availability)
4.2.8. e-Surgery
4.2.8.1. Overview
4.2.8.2. Product Applications & Services
A Sample Report on UK ePharmacy Market Analysis I Confidential 9
Table of Content
CONTENT
PG. NO.
4.2.8.3. Recent Developments
4.2.8.4. Partnerships Ecosystem
4.2.8.5. Financials (Based on Availability)
4.2.9. Simple Online Pharmacy
4.2.9.1. Overview
4.2.9.2. Product Applications & Services
4.2.9.3. Recent Developments
4.2.9.4. Partnerships Ecosystem
4.2.9.5. Financials (Based on Availability)
4.2.10. MedExpress
4.2.10.1. Overview
4.2.10.2. Product Applications & Services
A Sample Report on UK ePharmacy Market Analysis I Confidential 10
Table of Content
CONTENT
PG. NO.
4.2.10.3. Recent Developments
4.2.10.4. Partnerships Ecosystem
4.2.10.5. Financials (Based on Availability)
5. Reimbursement Scenario
46-53
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis
5.3. Reimbursement Process for Treatment
5.4 Reimbursement Process – Medicare
5.5 Reimbursement Process - Medicaid
6. Methodology & Scope
54-59
A Sample Report on UK ePharmacy Market Analysis I Confidential 11
UK ePharmacy Market Analysis
1. ePharmacy Overview
Overview of Global ePharmacy Trends
Top 10 ePharmacy Trends
▪
Please be aware that this sample report is
intended to provide you with a brief
Increased Online Presence
Prescription Delivery Services
overview of the kind of information and
Increased online presence of
Offering prescription delivery services
analysis that will be presented in the final
traditional and digital-only e-
for convenience and accessibility
report
pharmacies
▪
In this section you will get an
Mobile Applications
Expanded Product Range
understanding of the topic, which includes
Growing focus on mobile applications
Diversifying product range beyond
the prevalence of the disease, the
for convenient access to e-pharmacy
medications to include health and
application of medical devices, new
services.
wellness items
technology, and other details related to the
topic
Personalization and
AI-Powered Chatbots
Customization
AI-powered chatbots for real-time
▪
In order to obtain access to all of the
Utilizing customer data for
customer support and healthcare
information that you are seeking, you will
personalized recommendations and
information
need to purchase the final report
tailored healthcare solutions
▪
Final report will be comprehensive and
detailed, and it will include data, analysis,
Telehealth and Remote
Digital Health Records
trends, and other relevant information
Consultations
Integration of digital health records for
related to the topic or subject matter of
Integration of telehealth services for
easy access to medical history and
interest
remote consultations with healthcare
prescriptions
professionals
A Sample Report on UK ePharmacy Market Analysis I Confidential 13
1.1 Statistics at a Glance: The Burden of ePharmacy in the World (continued) Europe
~Revenue to reach
$XX Bn by 2027
North America
~ Market Size of
Asia
$XX Bn
-Fastest CAGR
UK
~Market Size of
UK Market
$XX Bn
~$XX Bn Market
A Sample Report on UK ePharmacy Market Analysis I Confidential 14
1.2 UK Overview
▪
Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪
In this section you will get an
understanding of the demographics of the
country/region, which includes the
6.73 crores
$31.3 Mn
population, GDP, healthcare expenditure
and other details related to the topic
Is the total
Gross domestic
population of UK in
product (GDP) of UK
▪
In order to obtain access to all of the
2021
information that you are seeking, you will
need to purchase the final report
▪
Final report will be comprehensive and
40.7
$46,510.28
detailed, and it will include data, analysis,
Is the median age
GDP per capita
trends, and other relevant information
in UK
of UK
related to the topic or subject matter of
interest
A Sample Report on UK ePharmacy Market Analysis I Confidential 15
1.3 Economic Overview: UK
Population of UK, (2020-2030)
GDP of UK, (2020-2030)
XX
XX
XX
XX
2020
2021
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
2020
2021
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population Split (2023)
▪
In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, By Gender
By Age Group
healthcare expenditure and other details related to the topic
▪
In order to obtain access to all of the information that you are 0-14
seeking, you will need to purchase the final report
15-24
Female
Male
▪
Final report will be comprehensive and detailed, and it will 51%
49%
25-54
include data, analysis, trends, and other relevant information 55-64
related to the topic or subject matter of interest
65+
A Sample Report on UK ePharmacy Market Analysis I Confidential 16
1.4 Overview of ePharmacy in UK
Highlights of ePharmacy in UK
▪
Please be aware that this sample report
is intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the
final report
US$0.89 Bn
39.35%
Is projected online
Is the user
▪
In this section you will get an
pharmacy revenue
penetration of e
understanding of the topic, which
in UK in 2023
Pharmacies in 2023
includes the prevalence of the disease,
in UK
the application of medical devices, new
technology, and other details related to
the topic in UK
47.14%
US$33.07
Is the expected user
Is the expected
▪
In order to obtain access to all of the
penetration of
average revenue per
information that you are seeking, you
ePharmacy in UK by
user (ARPU) of
will need to purchase the final report
2027
ePharmacy in UK
▪
Final report will be comprehensive and
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
A Sample Report on UK ePharmacy Market Analysis I Confidential 17
1.5 Healthcare Services in UK
UK Healthcare Services Market Forecast, 2022-2030 (in $Bn) XX
XX
XX
XX
XX
XX
XX
XX
XX
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
▪
Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report
▪
In this section you will get an understanding of the overall healthcare services market in UK, which includes the market size, current trends and other details related to the topic
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 18
1.6 Healthcare Scenario in UK
ePharmacy Development Process: The process of developing a ePharmacy drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the ePharmacy drug development process: o Preclinical Research: Researchers identify potential drug candidates and test them in the lab o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating ePharmacy o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches:
▪
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat Fast Track
serious conditions and fill an unmet medical need
Breakthrough
▪
A process designed to expedite the development and review of drugs which may demonstrate substantial Therapy
improvement over available therapy
Accelerated
▪
These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved Approval
based on a surrogate endpoint
Priority Review
▪
A Priority Review designation means FDA’s goal is to take action on an application within 6 months Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 19
1.7 Health Insurance Coverage: US
% of People by Type of Health Insurance Coverage
Number of People By Health Insurance Coverage
(2021)
Coverage Type
2020
2021
Change %
Uninsured
8.3
Total
327,521
328,074
With health insurance
91.7
Any health plan
299,230
300,887
0.4
Any private plan
217,896
216,366
–0.6
Any private plan
66.0
Employment-based
178,737
178,285
–0.2
Employment-based
54.3
Direct-purchase
10.2
Direct-purchase
33,869
33,555
–0.1
Marketplace
3.5
Marketplace coverage
10,924
11,389
0.1
TRICARE
2.5
TRICARE
9,165
8,299
–0.3
Any public plan
112,925
117,095
1.2
Any public plan
35.7
Medicare
58,541
60,226
0.5
Medicare
18.4
Medicaid
58,778
61,940
0.9
Medicaid
18.9
VA and CHAMPVA
2,967
3,151
0.1
VA and CHAMPVA
1.0
Uninsured
28,291
27,187
–0.4
▪
In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year
▪
More people had private health insurance (66%) than public coverage (35.7%)
▪
Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 20
1.8 Budget of UK Government for Public Insurance
Proposed Budget By Category
Outlays
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2022-31
Medicare
$769
$709
$766
$841
$840
$947
$1,014
$1,085
$1,227
$1,178
$1,325
$1,412
$10,633
In Billions Of Dollars
Medicaid
$458
$521
$571
$582
$616
$645
$674
$698
$734
$768
$801
$837
$6,926
Medicare
3.7%
3.2%
3.3%
3.4%
3.3%
3.6%
3.7%
3.8%
4.1%
3.8%
4.1%
4.2%
3.7%
As % Of GDP
Medicaid
2.2%
2.4%
2.4%
2.4%
2.4%
2.4%
2.4%
2.4%
2.5%
2.5%
2.5%
2.5%
2.4%
▪
National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪
Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪
Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪
Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪
Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪
Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪
Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪
Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪
Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪
Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 21
1.9 Mergers and Acquisitions
RCM M&A Deal Value Trend ($Bn)
RCM M&A Deal Volume Trend
$16.7
112
107
107
110
89
$11.7
82
$10.5
$7.7
$6.8
$6.0
1H 2020
2H 2020
1H 2021
2H 2021
1H 2022
2H 2022
1H 2020
2H 2020
1H 2021
2H 2021
1H 2022
2H 2022
Buyer Composition: Strategic Vs Financial (2020)
Buyer Type by Deal Size
41%
41%
42%
39%
($Mn)
59%
59%
58%
61%
Strategic Buyers
Financial Buyers
$0- $25
$25-$50
$50-$100
$100+
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 22
1.9 Mergers and Acquisitions (continued)
Latest Deals In UK
Amount /
Company Name
Type
Year
Key Pointers
Duration
▪
Zur Rose Group announced that the group had completed the Merger
-
2022
operational integration of the Medpex brand at the Heerlen facility Zur Rose partnership
with Medpex
▪
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired MedKeeper, a provider of modern, cloud-based
pharmacy management applications
Acquisition
-
July 2022
▪
MedKeeper strategically complements BD's existing presence in BD (Becton, Dickinson
the pharmacy – where the company has pioneered solutions in and Company)
compounding, logistics workflow, controlled substance
acquired MedKeeper
management and inventory optimization.tion
A Sample Report on UK ePharmacy Market Analysis I Confidential 23
1.9 Mergers and Acquisitions(continued)
Latest Deals In UK
Amount /
Company Name
Type
Year
Key Pointers
Duration
Merger
-
Acquisition
-
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 24
UK ePharmacy Market Analysis
2. Market Size and Forecasting
2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the
UK ePharmacy Market Forecast, 2022-2030 (in $Bn)
methodology and assumption
▪
Please be aware that this sample report
XX
is intended to provide you with a brief
XX
overview of the kind of information and
analysis that will be presented in the
final report
▪
In this section you will get an
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
and other details related to the topic
2023
2024
2025
2026
2027
2028
2029
2030
▪
In order to obtain access to all of the
Major Markets Patient
2.74
2.82
2.90
2.94
2.98
3.02
3.07
3.12
information that you are seeking, you
(Mn)
will need to purchase the final report
UK Patient Size (Bn)
0.51
0.61
0.68
0.69
0.70
0.71
0.72
0.73
▪
Final report will be comprehensive and
% of US Patients
18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
detailed, and it will include data,
analysis, trends, and other relevant
Global Market Size (Bn $)
3,620
3,780
3,950
4,128
4,314
4,508
4,711
4,937
information related to the topic or
subject matter of interest
UK Market Size (Bn $)
61
74
84
87
91
95
99
106
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 26
2.2 Snapshot of ePharmacy Market Segmentation
By Product Type
By Type
Prescription Medicine
Analgesics
Over the Counter Medicine
Skin Care
Dental Care
Cold and Flu
Vitamins and Minerals
Others
▪
In this section you will get an understanding of the segmentations which will cover the UK ePharmacy Market
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report A Sample Report on UK ePharmacy Market Analysis I Confidential 27
2.2.1 Market Segmentation: By Product Type
UK ePharmacy Market Share, By Product Type (2022)
▪
Prescription medication market in UK is
a significant component of the overall
ePharmacy treatment market
▪
Please be aware that this sample report
is intended to provide you with a brief
Over the Counter
overview of the kind of information and
Medications
analysis that will be presented in the
final report
▪
In order to obtain access to all of the
information that you are seeking, you
will need to purchase the final report
▪
Final report will be comprehensive and
Prescription
detailed, and it will include data,
Medications, 65%
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 28
2.2.2 Market Segmentation: By Type
UK ePharmacy Market Share, By Type (2022)
▪
Analgesics ePharmacy market in UK is
a significant component of the overall
ePharmacy market
Others, 12%
Vitamins and
▪
Please be aware that this sample report
Minerals, 10%
is intended to provide you with a brief
Analgesics
overview of the kind of information and
analysis that will be presented in the
final report
Clold and Flu, 15%
▪
In order to obtain access to all of the
information that you are seeking, you
will need to purchase the final report
▪
Final report will be comprehensive and
detailed, and it will include data,
Dental Care, 20%
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
Skin Care, 38%
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 29
UK ePharmacy Market Analysis
3. Market Dynamics
3.1 Market growth drivers
3.1.1 In UK the user penetration of ePharmacy will be 39.35% in 2023 and is expected to hit 47.14% by 2027
▪
ePharmacies offer the convenience of ordering medications and ePharmacy Use In UK
healthcare products online from the comfort of one's home. This accessibility appeals to individuals with busy lifestyles, limited mobility, or those living in remote areas
▪
Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
2010
2022
2030
A Sample Report on UK ePharmacy Market Analysis I Confidential 31
3.1 Market growth drivers
3.1.2 In the UK, ePharmacies play a crucial role in providing secure access to authentic and approved pharmaceuticals at affordable prices, with enhanced convenience through online platforms, home delivery, and improved digital payment infrastructure
▪
E-pharmacies can assist secure the provision of authentic and approved pharmaceuticals (a wide range of drugs that are safe for use) at reasonable rates (by removing intermediaries and giving discounts) and with greater ease of access (online platform, home delivery
& improved digital payment infrastructure)
▪
As a result of the convenience and value they provide, E-Pharmacies are predicted to be generally embraced in UK
▪
Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
A Sample Report on UK ePharmacy Market Analysis I Confidential 32
3.1 Market growth drivers (continued)
3.1.3 Efficiency of ePharmacies in delivering low-cost medical products, and combined with the increasing penetration of e-commerce is driving the UK ePharmacy market growth. User penetration will be 83.1% in 2023 and is expected to hit 86.3% by 2027
▪
A large patient pool globally prefers doorstep delivery of Penetration rate of e-commerce in UK
healthcare products owing to unavailability of certain medicines in retail pharmacy stores
▪
Additionally, ePharmacies lower the dependency of
chronically ill patients and elderly citizens towards third person for procurement of medicines and healthcare
supplies. Additionally, the increasing penetration and literacy regarding internet resources are projected to boost the market sales.
▪
Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information 2010
2022
2030
related to the topic or subject matter of interest
A Sample Report on UK ePharmacy Market Analysis I Confidential 33
3.2 Market restraints
3.2.1 In the UK, ePharmacies collect
3.2.2 In UK, there is currently no
3.2.3 In UK, implementing robust
and process user data, this user
unique or specific legislative
prescription verification systems
data also make ePharmacies
framework that solely governs the
while maintaining privacy can be
vulnerable to data breaches and
operations and practices of
a complex task
cyberthreats
ePharmacies
▪
To provide a flawless consumer
▪
Owing to there is no unique
▪
Validating prescriptions and
experience, these online
regime for these players, the
ensuring they are genuine poses
platforms rely substantially on
legal system that governs the
a challenge for ePharmacies
useful insights obtained from
offline sale of pharmacies
▪
Verifying prescriptions online is
user data (personal details,
equally applies to E-Pharmacy
crucial to prevent misuse or
purchasing habits, etc.)
▪
To safeguard the interests of
illegal distribution of medications.
▪
As a result, this data is
customers and to act as a
Implementing robust prescription
vulnerable to data breaches and
backbone in encouraging growth
verification systems while
other cyberthreats.
in this sector, the government
maintaining privacy can be
must establish a separate
complex
legislative framework for E-
Pharmacies in the near future
Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth
A Sample Report on UK ePharmacy Market Analysis I Confidential 34
UK ePharmacy Market Analysis
4. Competitive Landscape
4.1 Major Market Share
▪
UK ePharmacy market is a highly
Revenue of Major players in UK ePharmacy Market ($ Mn) competitive space, with many companies
developing and marketing ePharmacy
Company10
treatments
Company 9
▪
Some of the top companies in UK
ePharmacy market based on revenue and
Company 8
market share include
Company 7
▪
In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
Company 5
▪
Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
Company 3
related to the topic or subject matter of
interest
Company 2
Company 1
XX
A Sample Report on UK ePharmacy Market Analysis I Confidential 36
4.2 Key Company Profile
Key Note:
1
▪
Here is the list of top 10 companies which
Pharmacy2u
will cover in the final report
2
LloydsPharmacy
▪
Each company will have slides for
o Overview
3
Chemist4U
o Key details
4
The Independent
o Offerings
Pharmacy
o Name of products
5
AYP Healthcare
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
6
Well Pharmacy
o Mergers, Acquisitions and
Collaboration
7
Superdrug Online Doctor
o Financials
8
▪
If there are specific companies that you
e-Surgery
would like to be included in the report,
please let us know via email
9
Simple Online Pharmacy
▪
In order to obtain access to all of the
information that you are seeking, you will
10
MedExpress
need to purchase the final report
A Sample Report on UK ePharmacy Market Analysis I Confidential 37
4.2.1 Pharmacy2U
Solutions offered by Roche
▪ Pharmacy2U is one of the largest online pharmacies in the UK
Founded in: 1999
▪ It operates as an online platform that provides a range of
➢ Mark Livingstone - Chief
HQ: Leeds, United Kingdom
healthcare services and products
Executive Officer (CEO)
▪ Pharmacy2U's primary focus is on providing convenient access to
➢ Daniel Lee - Chief Financial
Type: Private
prescription medications and healthcare advice to customers Officer (CFO)
across the country
Revenue: $150 Mn
➢ Julian Harrison - Chief
▪ They operate under the supervision of the General
Commercial Officer (CCO)
Pharmaceutical Council (GPhC) and follow guidelines set by the Website: www.pharmacy2u.co.uk
Medicines and Healthcare products Regulatory Agency (MHRA)
➢ Andy Hornby - Chairman
ePharmacy
Recent Activity / Press Coverage
Services Offered by Pharmacr2U
April 2023, Pharmacy2U, the leading online pharmacy in the UK, Online Prescription Ordering
Medication Reminder Service
announced that they will be leveraging RingCentral’s UCaaS and Repeat Prescription
CCaaS services through the cloud, to offer next-level customer service Online Doctor Consultations
Management
in the age of digital transformation
NHS Prescription Service
Health Information and Advice
November 2022, Pharmacy2U Voted UK Number One Brand for Online Doctor Service
NHS Prescriptions
Customer Experience By Pharmacy2U
Medication Delivery
A Sample Report on UK ePharmacy Market Analysis I Confidential 38
4.2.1 Pharmacy2U (continued)
Partnerships Ecosystem
Current Corporate Partners
Current Clinical Trail Partners
A Sample Report on UK ePharmacy Market Analysis I Confidential 39
4.2.1 Pharmacy2U (continued)
Latest Deals - Mergers and Acquisitions
Amount /
Company Name
Type
Year
Key Pointers
Duration
▪
Pharmacy2U announced new partnership with Diabetes UK
▪
This partnership aims to help support people currently living with diabetes, as well as those at increased risk of type 2 diabetes October
across the UK
Merger
-
2021
▪
With 4.9 Mn people living in the UK with diabetes and an Pharmacy2U
estimated 13.6 million people at increased risk of developing type partnership with
2 diabetes, providing clear information and accessible guidance Diabetes UK
is crucial
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 40
4.2.1 Pharmacy2U (continued)
Revenues ($Bn), 2020-2030
▪
Pharmacy2U annual revenue for 2022 was
$150 Mn, a xx% increase from 2021.
Pharmacy2U annual revenue for 2021 was
$xx, a xx% increase from 2020.
70.9
70.3
▪
Revenue generated by Pharmacy2U in
63.3
2022 reflects the company's continued
growth and success in the healthcare
industry
2020
2021
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
▪
In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
Breakdown of Net Revenue by Segment, 2022
▪
In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
1
2
3
4
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 41
4.2.2 Company 2
Solutions offered by Company
Founded in:
HQ:
Type:
Revenue:
Website:
Drugs for
Recent Activity / Press Coverage
ePharmacy
Drugs
Indications
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 42
4.2.2 Company 2 (continued)
Partnerships Ecosystem
Major Distribution Partners
Major Vendor Partners
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 43
4.2.2 Company 2 (continued)
Latest Deals - Mergers and Acquisitions
Amount /
Company Name
Type
Year
Key Pointers
Duration
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 44
4.2.2 Company 2 (continued)
Revenues ($Bn), 2020-2030
▪
Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
xx
xx
xx
report
▪
In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
2020
2021
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
availability
▪
In order to obtain access to all of the
Breakdown of Net Revenue by Segment, 2022
information that you are seeking, you will
need to purchase the final report
▪
Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
1
2
3
4
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 45
UK ePharmacy Market Analysis
5. Reimbursement Scenario
5.1 Reimbursement Regulation
Medicare and Medicaid together provide
The reimbursement scenario in the US ePharmacy market is complex and can health insurance coverage for more than
vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider:
4 in 10 Americans
▪
Medicare:
o Medicare is a federal health insurance program for people aged 65 and Other Public
older, as well as people with certain disabilities or health conditions 1%
o Medicare covers many ePharmacy treatments, including chemotherapy, Other Private
radiation therapy, and some immunotherapies
3%
Uninsured
o
9%
However, coverage can be subject to strict guidelines and restrictions, Medicare
17%
such as the requirement for prior authorization
▪
Medicaid:
o Medicaid is a joint federal-state program that provides health insurance for people with low incomes
o Medicaid coverage for ePharmacy treatments can vary by state, and Medicaid
and CHIP
may be subject to limits on the amount and type of treatment covered 21%
▪
Private Insurance:
o Private insurance coverage for ePharmacy treatments can also vary widely depending on the insurer and the specific policy Employer-Sponsored
49%
o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Health Insurance Coverage, 2022
A Sample Report on UK ePharmacy Market Analysis I Confidential 47
5.1 Reimbursement Regulation (continued)
▪
Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to ePharmacy treatments by requiring insurers to cover certain preventive services, including ePharmacy screenings, without co-pays or deductibles o It also includes protections for people with pre-existing conditions, such as ePharmacy
▪
Reimbursement for New Treatments:
o Reimbursement for new ePharmacy treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage o This can create challenges for companies developing and marketing new treatments
▪
Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 48
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population)
Source of Funding
Spend on Healthcare (%of Current Health Expenditure) 100%
100%
100%
100%
100%
0%
Government Expenditure
0%
xx
xx
xx
xx
xx
7%
Public Healthcare
44.
0%
8%
46.
47.
51.
51.
Private Health Insurance
Coverage
Out of Pocket
Private Coverage
9%
1%
6%
5%
5%
38.
37.
35.
32.
31.
Other
NA
NA
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid
6.3%
4.08%
5.1%
3.8%
2.2%
2.4%
3.6%
GDP Growth (yoy)
Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities 14.7%
11.3%
15.5%
7.5%
4.2%
NA
NA
HC Spend Growth (yoy)
Medicaid is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources
Reimbursement Market Trends
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 49
5.2 Reimbursement Process
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪
Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪
Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided
▪
Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud
▪
Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule
▪
Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost of the service, such as deductibles, co-payments, or co-insurance In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 50
5.3 Reimbursement Process
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare FDA
provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪
Service or Treatment Provided: The healthcare provider performs a Market Authorization
service or treatment for the patient
▪
Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service Private Payers
Public Payers
provided
▪
Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment Health Technology Assessment
provided, and checking for any potential errors or fraud
▪
Payment: If the claim is approved, the insurance company or other 1
2
3
payer reimburses the healthcare provider for the service provided, Coding
Coverage
Payment
based on the negotiated payment rates or fee schedule
Coding depends on availability code while coverage and payment process decisions are made through an HTA.
Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 51
5.4 Reimbursement Process - Medicare
Medicare
▪ 100% population is covered under this scheme
Population Covered
▪ Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an individuals Medicare account
Provider Restrictions/
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community Selection
center and over 100 surgery centers, ePharmacy centers, colonoscopy centers and screening centers)
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits Services Covered
▪ Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by using up to $200 per patient per year from their Medicare account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs used for cosmetic purposes such as slimming pills and hair loss pills cannot be claimed from this account
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures Level of Coverage/ Assurance
▪ Outpatient scans/ diagnostics for ePharmacy up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month per patient
▪ Renal ePharmacy up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
▪ DRG with Activity Based Funding for public providers Mechanism of Coverage
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility
▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 52
5.5 Reimbursement Process - Medicaid
Medicaid
▪ 38% population is covered under this scheme
Population Covered
▪ Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease Provider Restrictions/
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community Selection
center and over 100 surgery centers, ePharmacy centers, colonoscopy centers and screening centers)
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits Services Covered
▪ Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by using up to $200 per patient per year from their Medicaid account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs used for cosmetic purposes such as slimming pills and hair loss pills cannot be claimed from this account
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures Level of Coverage/ Assurance
▪ Outpatient scans/ diagnostics for ePharmacy up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month per patient
▪ Renal ePharmacy up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
▪ DRG with Activity Based Funding for public providers Mechanism of Coverage
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility
▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account Illustrative
A Sample Report on UK ePharmacy Market Analysis I Confidential 53
UK ePharmacy Market Analysis
6. Methodology & Scope
▪
Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions
▪
We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources
▪
For forecasting, the following parameters are considered:
❑
Market drivers and restraints along with their current and expected impacts
❑
Technological scenario and expected developments
❑
End use industry trends and dynamics
❑
Trends in the consumer behavior
❑
Regulatory scenario and expected developments
❑
Current capacity and expected capacity additions up to 2030
▪
We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate
▪
We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-sensitive, reflecting the most recent value and volume of the market across regions
▪
All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪
Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)
Analysis Methodology
Our Analysis Methodology involves three critical stages: Data
Market Data Analysis
Interpretation &
Collection
& Statistical Model
Presentation
Secondary
Analysis &
Market Trends
Research
Interpretation
Primary
Market Sizing &
Insights
Research
Analysis
Proprietary
Data Triangulation &
Presentation &
Database
Validation
Reporting
Data Triangulation & Data Validation
Top Down Approach
Final
Final Market size break up to
Market
rest of segmentation
Size
Validation from
Arriving at market size
Primary Interview
of each segment
Summarization of revenue
generated from companies
Validation from
to arrive at total market size
Primary Interview
Revenue generated by products &
Final
services offered by companies
Summary
Bottom Up Approach
Key Benefits for Stakeholders from this Report Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors
Time Frame
Report Attribute
Details
Quantitative Units
Revenue in USD Million/Billion (Mn/Bn)
Base Year for
2022
Estimation
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Report Coverage
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
Customized Report
that is currently not a part of our scope as a
2023-
Forecast
part of customization
2030
Period
Pricing and purchase
Avail customized purchase options to meet
options
your exact research needs
A division of
Lifesciences Market
Research Reports you
can trust
Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
Get actionable insights to
take informed business
decisions
A large database of over 30,000 syndicated
market research reports in Healthcare Services
and healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Elevate your business plans
with in-depth market analysis
and industry intelligence
Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Gain a competitive edge with
Insights10's customized
healthcare research solutions
Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Market Research Reports
across various categories
Healthcare Services
Digital
Medical
Healthcare
OTC &
Clinical
(Diseases & Drugs)
Health
Devices
Services
Nutraceuticals
Trials
FEATURED REPORTS
FREE SAMPLE REPORTS
TRENDING TOPICS
What makes us different?
30000+
22000+
2000+
1200+
Life science
Country
Rare & orphan
Reports
Market Research
Specific
Disease
Published
Reports
Reports
Reports
Annually
Table of Contents
Market Overview
Competitive Landscape
1
6
Growth Drivers &
Key Company Profiles
2
7
Growth Restraints
Epidemiology &
Policy & Regulatory
3
8
Disease type
Landscape
insights on
which our
reports are
Market Segmentation
based
4
9
Reimbursement Scenario
Market Share
5
10
Factors Driving Future Growth
Our Services
Market Research
Customized
Primary
Reports
Reports
Research
Database
Full-Time
Conference
Service
Engagement
Coverage
Competitive
Regulatory
Subscription
Intelligence
Compliance
Over the years, we have developed an in-depth experience of executing market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, UK and
Asia Pacific regions
Research Projects Done
Our Research Process
01
02
03
04
05
Identification of
Market
Collection of
Collaboration
Verification &
Data
Dynamics
Data
of Data
Analysis
Statistical Databases
Company Websites/Annual Reports
Data
Sources
Trade Publications
We have access to multiple highly
Online Databases
reliable free and subscription data
sources. We have many years of
experience to understand which
Published Research Reports
sources are more dependable for what
and which to prefer for the reliable and
Whitepapers
latest information.
Press Releases of Key Market Players
What kind of data is presented
in our reports?
Our reports present data, which is:
Reliable
Expert-verified
Real
Comprehensive
Easy to read
The report is
The data is prepared
Allowing you to
Covers everything
You do not have to
prepared using a
by a team of highly
confidently make
you would need to
be a market expert
proven methodology
qualified &
smarter business
know about the
to understand what
and insightful
experienced research
and strategic
market including
really is happening
research
analysts & vetted by
decisions
market size,
on the market and
our local associates
competitive analysis
how it works
& much more
The team
“The business decision-making process is no longer as straightforward as it used to be. It requires insights generated at the right time, based on reliable data interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market research and are committed to providing our clients with the right intelligence and insights to make business decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with some of the best organizations in the world,
generating insights that provides substantial competitive advantage.”
Dr. Purav Gandhi
Founder & CEO
Leadership Team
Dr. Purav Gandhi
Anish Swaminathan
Mukesh Nayak
Ritu Baliya
Founder & CEO
Director
Head – Marketing & Research
Engagement Manager
Purav is a physician and an entrepreneur
Anish has 15+ years of experience
Mukesh is an engineering graduate with
Ritu has over 6 years of experience in
with 12+ years of experience in Healthcare
in management consulting in the
an MBA in Marketing. He is a seasoned
strategy building, market assessments,
& Life Sciences industry spanning across
Life Sciences sector, and has
healthcare market research & marketing
market sizing, and RWE for global MNC
strategy, market access, health informatics
worked with diverse multinational
professional with a progressive
healthcare & biopharma clients across diff.
and RWE, digital health, analytics and data
firms in the US, India, Middle East
experience of over 20 years in Life
markets (America, Europe, UK, APAC and
science. Purav studied medicine from
and APAC regions. His primary
Sciences, Pharma and Medical Device
Middle East). Her areas of expertise include:
Gujarat University and also completed his
area of interest is Customer and
sectors. With an in-depth understanding
Indentifying emerging trends in life sciences
MBA from IIM-Kozhikode. Purav started
Market Strategy, Market Access,
of primary research, he has conducted
industry, Competitor landscape assessment,
his career with Deloitte working on strategy
and Digital Health with special
hundreds of interviews of various
Disease opportunity assessments etc. She
consulting engagements and also co-
focus on emerging markets like
stakeholders in pharma & healthcare &
is a pro in secondary and primary research
founded ConvergeHealth by Deloitte.
UK, Middle East and APAC.
completed several research projects
with a deep domain expertise in healthcare
across life sciences industry.
sector.
Our Team
Our Clients
Our Clients
… and many more
Do you have
any questions?
We would be happy to help.
Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
Thank you
We truly appreciate your business and
look forward to serving you.
www.insights10.com
